{"nctId":"NCT01975675","briefTitle":"Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection","startDateStruct":{"date":"2013-10"},"conditions":["Chronic HCV Infection"],"count":341,"armGroups":[{"label":"LDV/SOF (treatment naive)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"LDV/SOF+RBV (treatment naive)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]},{"label":"LDV/SOF (treatment experienced)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"LDV/SOF+RBV (treatment experienced)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]}],"interventions":[{"name":"LDV/SOF","otherNames":["GS-7977","PSI-7977","GS-5885"]},{"name":"RBV","otherNames":["Copegus®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Body weight ≥ 40 kg\n* HCV RNA ≥ 10\\^5 IU/mL at screening\n\nExclusion Criteria:\n\n* Current or prior history of any clinically-significant illness (other than HCV)\n* Pregnant or nursing female or male with pregnant female partner\n* Chronic liver disease of a non-HCV etiology\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12), Treatment-naive, Noncirrhotic Participants","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response at 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR 24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks after stopping study treatment, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Virologic Failure","description":"Virologic failure was defined as\n\nOn-treatment virologic failure:\n\n* Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n* Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n* Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n\nVirologic relapse:\n\n\\- Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":171},"commonTop":["Nasopharyngitis","Headache","Anaemia","Pruritus","Rash"]}}}